• home
  • about us
    • the advantage
    • key facts
    • where we are
    • where we invest
    • management team
    • funds
  • portfolio
    • companies
    • CEOs
  • news
  • investments
    • focus
      • prevention & nutraceuticals
      • medical foods OTC, Rx
      • enabling technologies
      • brands & channels
      • diagnostics
    • criteria
    • process
  • your business
  • careers
  • contact us
    • the bahamas
    • united kingdom
    • switzerland
    • new zealand

portfolio

MSI Methylation Sciences Inc.

MSI Methylation Sciences Inc. (MSI) is focused on developing pharmaceuticals which are proven to be clinically effective but which have yet to be exploited in major pharmaceutical markets. MSI is actively exploring several proprietary formulations of s-adenosyl methionine with an initial clinical focus on the treatment of depression.

MSI Methylation Sciences Raises EUR13.5 Million From Inventages Venture Capital via Series A Institutional
2011-09-29
  • This new investment will help fund the clinical development of MSI's formulations of s-adenosyl methionine (SAMe) to clinical proof of concept. MSI's leads are the first generation of MSI SAMe formulations with superior properties and are ready for clinical trials.
  • "We are delighted to have successfully completed this fundraising and to have secured sufficient funds to take our lead molecule into formal clinical development," said Barry Guld, Chief Executive Officer and President ofMSI. "We look forward to working with the Inventages team."

Read the full article...

Barry Guld, MSI:
 "The team at Inventages is the perfect partner for us."
www.methylationsciences.com
www.methylationsciences.com
Back to portfolio ...
Erik van den Berg, AM-Pharma
Erik van den Berg, AM-Pharma:
"Inventages has a broad network of excellent service providers and experts and can provide board room access with potential strategic partners." More...
Terms Print Top
© 2012 Inventages